Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran.
Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
2076 views · 35 likes · 15 reposts · 0 replies
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgSource: Stephen V Liu, MD · x.com